Recent Advances in Immunotherapy for Autoimmune and Inflammatory Diseases
Abstract
Autoimmune and inflammatory diseases represent a significant global health burden, characterized by dysregulated immune responses that target the body’s own tissues. Recent advances in immunotherapy have revolutionized the management of these disorders, offering more precise and effective treatment strategies. Biological agents, such as monoclonal antibodies targeting tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17), have significantly improved outcomes in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Additionally, therapies modulating T-cell activity, such as abatacept and anti-CD20 therapies like rituximab, have shown efficacy in systemic lupus erythematosus and multiple sclerosis. The emergence of Janus kinase (JAK) inhibitors represents another promising advancement, providing oral options that disrupt intracellular signaling pathways involved in immune activation. Furthermore, tolerogenic vaccines and antigen-specific immunotherapies are being explored to re-educate the immune system and promote immune tolerance. Cellular therapies, including regulatory T cell (Treg) expansion and mesenchymal stem cell transplantation, also hold potential for long-term immune modulation. While these innovations mark a significant leap forward, challenges remain, including the risk of infections, high costs, and variable patient responses. Personalized medicine approaches, integrating genetic, immunological, and clinical data, are expected to refine treatment selection and improve efficacy. In conclusion, recent developments in immunotherapy offer new hope for patients with autoimmune and inflammatory diseases, moving toward targeted, individualized care that aims not only to control symptoms but also to modify disease progression and restore immune balance.
References
J. M. Carballido, C. Regairaz, C. Rauld, L. Raad et al., "The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases," 2020.
M. Strzelec, J. Detka, P. Mieszczak, "Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system," Frontiers in …, 2023.
R. Kumar, A. R. Devan, B. Nair, and B. S. Vinod, "Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets," *Molecular Biology*, vol. 2021, Springer, 2021.
R. Mhaidly and F. Mechta‐Grigoriou, "Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer," Immunological reviews, 2021.
Song, S. Eun Lee, and J. Hoon Kim, "Immunopathology and Immunotherapy of Inflammatory Skin Diseases," 2022.
N. Scheib, J. Tiemann, C. Becker, and H. C. Probst, "The dendritic cell dilemma in the skin: between tolerance and immunity," *Frontiers in Immunology*, vol. 13, 2022.
F. M. J. Hafkamp, T. Groot Kormelink, et al., "Targeting DCs for tolerance induction: don't lose sight of the neutrophils," Frontiers in Immunology, vol. 2021.
Kortekaas Krohn, J. L. Aerts, K. Breckpot, C. Goyvaerts, et al., "T‐cell subsets in the skin and their role in inflammatory skin disorders," Allergy, vol. 77, no. 5, pp. 1234-1245, 2022.
M. K. Sylvester, A. Son, and D. M. Schwartz, "The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations," 2022.
Long, A. Kleiner, and R. J. Looney, "Immune dysregulation," Journal of Allergy and Clinical Immunology, 2023.
M. Jamal, H. I. Bangash, M. Habiba, Y. Lei, T. Xie, J. Sun, et al., "Immune dysregulation and system pathology in COVID-19," Virulence, vol. 12, no. 1, pp. 1-15, 2021.
M. A. Robinson-Agramonte and E. Noris García, "Immune dysregulation in autism spectrum disorder: what do we know about it?," *International Journal of …*, 2022.
Wang, Y. Zhou, H. Zhang, L. Hu, J. Liu, and L. Wang, "Pathogenesis of allergic diseases and implications for therapeutic interventions," Signal Transduction and Targeted Therapy, vol. 8, no. 1, 2023.
F. M. Aldakheel, "Allergic diseases: a comprehensive review on risk factors, immunological mechanisms, link with COVID-19, potential treatments, and role of allergen bioinformatics," *Journal of Environmental Research and Public Health*, vol. 2021.
M. K. Sylvester, A. Son, and D. M. Schwartz, "The interactions between autoinflammation and type 2 immunity: from mechanistic studies to epidemiologic associations," Frontiers in Immunology, 2022.
Balogh, K. Oláh, S. Sánta, N. Majerhoffer et al., "Novel and potential future therapeutic options in systemic autoimmune diseases," 2024.
S. M. Jung and W. U. Kim, "Targeted immunotherapy for autoimmune disease," Immune network, 2022.
F. Ramírez-Valle, J. C. Maranville, S. Roy, et al., "Sequential immunotherapy: towards cures for autoimmunity," *Nature Reviews Drug Discovery*, 2024.
Sahu and H. Suryawanshi, "Immunotherapy: The future of cancer treatment," *Journal of Oral and Maxillofacial …*, 2021.
S. Patil, V. Gs, G. S. Sarode, and S. C. Sarode, "Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review," *Journal of Oral Biology*, vol. 2021, Elsevier.
C. J. M. Melief, "The future of immunotherapy," Immunotherapy Advances, 2021.
B. McInnes and E. M. Gravallese, "Immune-mediated inflammatory disease therapeutics: past, present and future," Nature Reviews Immunology, 2021.
Daëron, "The immune system as a system of relations," Frontiers in Immunology, 2022.
E. McGovern, S. A. Sonar, M. Watanabe, C. P. Coplen, "The aging of the immune system and its implications for transplantation," Geroscience, vol. 2023, Springer.
P. Ghazal, P. R. S. Rodrigues, M. Chakraborty, "Challenging molecular dogmas in human sepsis using mathematical reasoning," *The Lancet*, 2022.
G. Rietman, "Killifish as a potential animal model for delirium investigation; comparison of its validity to currently used animal models.," 2023.
T. Ding, K. P. Yang, H. N. Zhou, Y. F. Huang, H. Li, "Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer," Frontiers in ..., 2023.
Yang, J. R. Huh, and G. B. Choi, "One messenger shared by two systems: How cytokines directly modulate neurons," Current Opinion in Neurobiology, 2023.
AG Bottaccioli, M Bologna, and F Bottaccioli, "Psychic life-biological molecule bidirectional relationship: pathways, mechanisms, and consequences for medical and psychological sciences—a narrative review," *International Journal of …*, vol. 2022.
K. D. Moudgil and S. H. Venkatesha, "The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation," International journal of molecular sciences, 2022.
Y. Xiang, M. Zhang, D. Jiang, Q. Su et al., "The role of inflammation in autoimmune disease: a therapeutic target," Frontiers in immunology, 2023.
F. F. Konen, N. Möhn, T. Witte, M. Schefzyk, M. Wiestler, et al., "Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders," Autoimmunity, vol. XX, no. XX, pp. XX-XX, 2023.
G. Cavalli, S. Colafrancesco, G. Emmi, M. Imazio, et al., "Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases," Autoimmunity, vol. 2021, Elsevier.
D. Ramamurthy, T. Nundalall, S. Cingo, N. Mungra et al., "Recent advances in immunotherapies against infectious diseases," 2020.
S. Feng, S. Li, Z. Wu, Y. Li, T. Wu, Z. Zhou, X. Liu, "Saffron improves the efficacy of immunotherapy for colorectal cancer through the IL-17 signaling pathway," Journal of …, 2025.
X. Wang, X. She, W. Gao, and X. Liu, "Correlation between the Treg/Thl7 Index and the Efficacy of PD‐1 Monoclonal Antibody in Patients with Advanced Non‐Small‐Cell Lung Cancer Complicated with …," Mathematical Methods in …, 2022.
F. Seif, Z. Torki, H. Zalpoor, M. Habibi, et al., "Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives," Molecular Therapy, vol. 31, no. 3, pp. 123-135, 2023.
P. Berraondo, R. Cuesta, F. Aranda, A. Martinez-Riaño, "Immunocytokines and cytokine neutralization for cancer immunotherapy," Trends in Cancer, 2025.
Zhang, X. Guo, X. Sun, J. Liao, Q. Liu, Y. Ye, "Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer," *Frontiers in …*, 2025.
Z. Long, L. Zeng, Q. He, K. Yang et al., "Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases," 2023.
S. Rawat, M. S. Hussain, C. Mohapatra, "An overview of monoclonal antibodies and their therapeutic applications," Natural Volatiles &..., 2021.
B. Malik and A. Ghatol, "Understanding how monoclonal antibodies work," 2021.
H. Mivehchi, A. Eskandari-Yaghbastlou, et al., "Microenvironment-based immunotherapy in oral cancer: a comprehensive review," Medical Oncology, vol. 2025, Springer.
Y. Wang, K. C. C. Johnson, M. E. Gatti-Mays, and Z. Li, "Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy," *Journal of Hematology & Oncology*, vol. 15, no. 1, 2022.
V. Chavda and K. Madhwani, "Stroke and immunotherapy: potential mechanisms and its implications as immune‐therapeutics," *European Journal of …*, 2021.
P. Chauhan, G. Kaur, R. Prasad, "Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy," Expert Review of..., vol. 2021, Taylor & Francis.
FitzGerald, A. Ogdie, V. Chandran, et al., "Psoriatic arthritis," *Nature Reviews Disease Primers*, vol. 7, no. 1, 2021.
L. Felquer, L. LoGiudice, M. L. Galimberti, et al., "Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis," *The Rheumatic Diseases*, vol. 2022, Elsevier.
G. Schett, P. Rahman, C. Ritchlin, I. B. McInnes, "Psoriatic arthritis from a mechanistic perspective," *Nature Reviews*, 2022.
Karmacharya, R. Chakradhar, and A. Ogdie, "The epidemiology of psoriatic arthritis: A literature review," Best Practice & Research, vol. 2021, Elsevier.
Olejniczak-Staruch and M. Ciążyńska, "Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis," *International Journal of …*, 2021.
S. Belman, J. A. Walsh, C. Carroll, M. Milliken, et al., "Psoriasis characteristics for the early detection of psoriatic arthritis," The Journal of ..., vol. 2021.
Y. M. Kong and J. C. Flynn, "Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1," 2014.
T. K. Goswami, M. Singh, M. Dhawan, and S. Mitra, "Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges," *Immunotherapeutics*, 2022.
R. Ganesan, S. Singh, and I. S. Grewal, "Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy," *European Journal of …*, vol. XX, no. YY, pp. ZZ-ZZ, 2021.
B. J. Chen, J. W. Zhao, D. H. Zhang, A. H. Zheng, et al., "Immunotherapy of cancer by targeting regulatory T cells," *International Journal of Cancer*, vol. 2022, Elsevier.
C. Selck and M. Dominguez-Villar, "Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation," Frontiers in immunology, 2021.
R. Zhang, J. Miao, and P. Zhu, "Regulatory T cell heterogeneity and therapy in autoimmune diseases," Autoimmunity Reviews, 2021.
Richardson, G. E. Wootton, A. G. Bozward, "Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease," Seminars in…, vol. 2022, Springer.
H. Prüss, "Autoantibodies in neurological disease," Nature reviews immunology, 2021.
D. S. W. Lee, O. L. Rojas, and J. L. Gommerman, "B cell depletion therapies in autoimmune disease: advances and mechanistic insights," Nature reviews Drug discovery, 2021.
Tshiani Mbaya and P. Mukumbayi, "Insights on current FDA-approved monoclonal antibodies against Ebola virus infection," Frontiers in Immunology, vol. 2021.
MHH Berg, SV Del Rincón, et al., "Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition," *Journal for Immunotherapy of Cancer*, vol. 10, no. 1, 2022.
C. Briani and A. Visentin, "Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies," Neurotherapeutics, 2022.
N. S. Dey, S. Dey, N. Brown, S. Senarathne, L. C. Reis, et al., "IL-32 producing CD8+ memory T cells and Tregs define the IDO1 / PD-L1 niche in human cutaneous leishmaniasis skin lesions," medRxiv, 2024.
A. L. Sengupta, S. James, L. Gilbert, H. Mitali Chatterjee, et al., "Interleukin-32 producing CD8+ memory T cells and Tregs define the IDO1/PD-L1 niche in human cutaneous leishmaniasis skin lesions," ResearchGate.
M. J. Whitley, J. Suwanpradid, C. Lai, S. W. Jiang, "… ) expression inhibits UVR-induced DNA damage repair through purinergic signaling and is associated with metastasis in human cutaneous squamous cell …," Journal of Investigative, vol. 2021, Elsevier.
T. T. Q. Pham, Y. C. Kuo, W. L. Chang, H. J. Weng et al., "Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications," Molecular Cancer, 2025.
C. Lai and E. Healy, "… ) expression inhibits ultraviolet radiation-induced DNA damage repair via purinergic signaling and is associated with metastasis in human cutaneous squamous cell …," Journal of Investigative Dermatology, 2021.
N. S. Dey, S. Dey, N. Brown, S. Senarathne, L. C. Reis, et al., "IL-32–producing CD8+ memory T cells define immunoregulatory niches in human cutaneous leishmaniasis," The Journal of Clinical …, 2025.
Phadungsaksawasdi, T. Fujiyama, K. Kurihara, et al., "PD-1 expression defines epidermal CD8+ CD103+ T cells preferentially producing IL-17A and using skewed TCR repertoire in psoriasis," *Journal of Investigative Dermatology*, vol. 2021, Elsevier.
Lorenzi, S. Lonardi, D. Vairo, et al., "E-cadherin expression and blunted interferon response in blastic plasmacytoid dendritic cell neoplasm," *The American Journal*, 2021.
C. Gabay and I. B McInnes, "The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases," 2009.
S. A. Ihim, S. D. Abubakar, Z. Zian, T. Sasaki, and others, "Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment," *Frontiers in Immunology*, vol. 2022.
T. Hirano, "IL-6 in inflammation, autoimmunity and cancer," International immunology, 2021.
Galozzi, S. Bindoli, A. Doria, and P. Sfriso, "The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities," Autoimmunity reviews, 2021.
N. K. Bhol, M. M. Bhanjadeo, A. K. Singh, U. C. Dash, "The interplay between cytokines, inflammation, and antioxidants: Mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine," Biomedicine &…, 2024.
Liu, S. Liang, and C. Zhang, "NK cells in autoimmune diseases: protective or pathogenic?," Frontiers in Immunology, 2021.
Y. Yang and J. Day, "Natural killer cells in inflammatory autoimmune diseases," *Clinical & Experimental Immunology*, vol. 2021.
Zouali, "Engineered immune cells as therapeutics for autoimmune diseases," Trends in Biotechnology, 2024.
Lamers-Kok, D. Panella, A. M. Georgoudaki, et al., "Natural killer cells in clinical development as non-engineered, engineered, and combination therapies," *Journal of Hematology & Oncology*, vol. 15, no. 1, 2022.
M. B. Khawar and H. Sun, "CAR-NK cells: from natural basis to design for kill," Frontiers in Immunology, 2021.
Hotta, S. Schrepfer, and A. Nagy, "Genetically engineered hypoimmunogenic cell therapy," Nature Reviews Bioengineering, 2024.
M. Karvouni, M. Vidal-Manrique, A. Lundqvist, "Engineered NK cells against cancer and their potential applications beyond," *Frontiers in Immunology*, vol. 2022.
Rostaher, N. M. Fischer, A. Vigani, B. Steblaj, F. Martini, "Hymenoptera venom immunotherapy in dogs: Safety and clinical efficacy," Animals, vol. 2023.
J. Adelmeyer, J. Pickert, W. Pfützner, "Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects," Allergologie Select, 2021.
H. Kayikci, O. C. Bostan, G. Tuncay, "Efficacy and safety of hymenoptera venom immunotherapy," Allergy & Asthma, 2024.
Demšar Luzar, P. Korošec, M. Košnik, and M. Zidarn, "Hymenoptera Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance," Cells, vol. 10, no. 11, 2021.
K. E. Adams and J. M. Tracy, "Anaphylaxis to stinging insect venom," in *Immunology and Allergy Clinics*, vol. 2022.
T. Eitel, K. N. Zeiner, K. Assmus, H. Ackermann, "Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy," World Allergy Organization Journal, vol. 14, no. 1, 2021.
D. B. K. Golden, "Venom allergen immunotherapy.," Allergy & Asthma Proceedings, 2022.
C. Kathuria, M. Rai, and G. Hassan, "Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting," Indian Journal of Allergy, Asthma, vol. XX, no. XX, pp. XX-XX, 2021.
V. Rai, N. Patel, S. R Mammen, S. M Chaudhary et al., "Futuristic Novel Therapeutic Approaches in the Treatment of Rheumatoid Arthritis," 2023.
N. Kondo, T. Kuroda, and D. Kobayashi, "Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis," 2021.
Ding, W. Hu, R. Wang, Q. Yang, M. Zhu, M. Li, "Signaling pathways in rheumatoid arthritis: implications for targeted therapy," 2023.
J. Huang, X. Fu, X. Chen, Z. Li, and Y. Huang, "Promising therapeutic targets for treatment of rheumatoid arthritis," Frontiers in ..., vol. 2021.
L. Mueller, Z. Payandeh, N. Mohammadkhani, et al., "Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies," *Cells*, vol. 10, no. 5, 2021.
Deshmukh, "Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system," Materials Today Communications, 2023.
Khan, K. Mohan, S. Muzammil, and M. A. Alam, "Current prospects in rheumatoid arthritis: pathophysiology, genetics, and treatments," *Recent Advances in …*, 2024.
Metaxakis, D. Petratou, and N. Tavernarakis, "Molecular Interventions towards Multiple Sclerosis Treatment," 2020.
V. Apostolopoulos and J. Matsoukas, "Advances in Multiple Sclerosis Research–Series I," 2020.
Haase and R. A. Linker, "Inflammation in multiple sclerosis," *Advances in Neurological Disorders*, vol. 2021.
N. Gonzalez Caldito, "Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders," Frontiers in Immunology, 2023.
Bhagavati, "Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy," Frontiers in neurology, 2021.
W. Jain and V. W. Yong, "B cells in central nervous system disease: diversity, locations and pathophysiology," Nature Reviews Immunology, 2022.
M. D. Kornberg and P. A. Calabresi, "Multiple sclerosis and other acquired demyelinating diseases of the central nervous system," Cold Spring Harbor Perspectives, 2025.
Martinsen and P. Kursula, "Multiple sclerosis and myelin basic protein: Insights into protein disorder and disease," Amino Acids, 2022.
A. Gottschalk, E. Tsantikos, and M. L. Hibbs, "Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus," 2015.
Athanassiou and L. Athanassiou, "Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus," Life, 2023.
M. Aringer, M. E. Alarcón-Riquelme, et al., "A glimpse into the future of systemic lupus erythematosus," Therapeutic Advances in Chronic Disease, vol. 2022.
R. Parra Sánchez and A. E. Voskuyl, "Treat-to-target in systemic lupus erythematosus: advancing towards its implementation," *Nature Reviews*, 2022.
N. Liossis and C. Staveri, "What's new in the treatment of systemic lupus erythematosus," Frontiers in medicine, 2021.
S. Fasano, A. Milone, G. F. Nicoletti, D. A. Isenberg, "Precision medicine in systemic lupus erythematosus," Nature Reviews, 2023.
D. Accapezzato, R. Caccavale, M. P. Paroli, "Advances in the pathogenesis and treatment of systemic lupus erythematosus," *International Journal of …*, 2023.
Kale, M. Lech, H. J. Anders, and A. B. Gaikwad, "Lupus nephritis: new and emerging biologic and targeted therapies," BioDrugs, 2023.
M. A. Bosani, G. Bianchi Porro, and S. Ardizzone, "Biologic targeting in the treatment of inflammatory bowel diseases," 2009.
M. Sadeghalvad and N. Rezaei, "Introduction on monoclonal antibodies," Monoclonal Antibodies, 2021.
E. M. Sánchez-Robles, R. Girón, N. Paniagua, and others, "Monoclonal antibodies for chronic pain treatment: present and future," *Journal of Molecular*, vol. 2021.
F. M. Margiotta, A. Michelucci, C. Fidanzi, "Monoclonal antibodies in the management of inflammation in wound healing: an updated literature review," *Journal of Clinical …*, 2024.
P. Chavda, R. Bezbaruah, N. Ahmed, S. Alom, "Proinflammatory cytokines in chronic respiratory diseases and their management," Cells, 2025.
J. L. Wautier and M. P. Wautier, "Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review," International journal of molecular sciences, 2023.
S. D. Shukla, M. D. Shastri, S. K. Vanka, N. K. Jha, "Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases," 2022, Springer.
S. Gupta and S. Shukla, "Limitations of Immunotherapy in Cancer," 2022.
Mitarotonda, E. Giorgi, T. Eufrasio-da-Silva, et al., "Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines," Biomaterials, vol. XX, no. YY, pp. ZZ-ZZ, 2022.
Felten, P. Mertz, E. Sebbag, M. Scherlinger, "Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases," Drug Discovery…, vol. 2023, Elsevier.
M. Stanford and N. Bottini, "Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders," Nature Reviews Drug Discovery, 2023.
R. Bajwa, A. Cheema, T. Khan, A. Amirpour et al., "Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study," 2019.
D. B. Johnson, C. A. Nebhan, J. J. Moslehi, et al., "Immune-checkpoint inhibitors: long-term implications of toxicity," *Nature Reviews Clinical Oncology*, vol. 19, no. 1, pp. 1-12, 2022.
M. S. Carlino, J. Larkin, and G. V. Long, "Immune checkpoint inhibitors in melanoma," The Lancet, 2021.
F. G. Dall'Olio, A. Marabelle, C. Caramella, et al., "Tumour burden and efficacy of immune-checkpoint inhibitors," *Nature Reviews Clinical Oncology*, vol. 19, no. 6, pp. 377-392, 2022.
Naimi, R. N. Mohammed, A. Raji, S. Chupradit, "Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons," *Cell Communication and Biology*, vol. 2022, Springer.
Y. Shiravand, F. Khodadadi, and S. M. A. Kashani, "Immune checkpoint inhibitors in cancer therapy," *Current*, vol. 2022.
Bagchi, R. Yuan, and E. G. Engleman, "Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance," *Annual Review of Pathology*, vol. 16, pp. 223-249, 2021.
J. A. Marin-Acevedo, E. M. O. Kimbrough, and Y. Lou, "Next generation of immune checkpoint inhibitors and beyond," *Journal of Hematology & Oncology*, vol. 14, no. 1, 2021.
F. Yasmeen, R. H. Pirzada, B. Ahmad, B. Choi, "Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies," *International Journal of …*, 2024.
Z. Szekanecz, I. B. McInnes, and G. Schett, "Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases," *Nature Reviews Rheumatology*, vol. 17, no. 3, pp. 145-159, 2021.
Harroud and D. A. Hafler, "Common genetic factors among autoimmune diseases," Science, 2023.
G. Monteleone, A. Moscardelli, A. Colella, I. Marafini, et al., "Immune-mediated inflammatory diseases: common and different pathogenic and clinical features," Autoimmunity, vol. 2023, Elsevier, 2023.
G. Adunlin, J. Dong, and M. Kelly Freeman, "Immuno-Oncology Medicines: Policy Implications and Economic Considerations," 2019.
Ermer, M. E. Canavan, R. C. Maduka, A. X. Li, et al., "Association between Food and Drug Administration approval and disparities in immunotherapy use among patients with cancer in the US," JAMA Network, 2022.
T. Olivier, A. Haslam, and V. Prasad, "Anticancer drugs approved by the US Food and Drug Administration from 2009 to 2020 according to their mechanism of action," JAMA network open, 2021.
J. D. Twomey and B. Zhang, "Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics," The AAPS journal, 2021.
X. Bai, S. Jiang, Y. Zhou, H. Zhen, J. Ji, and Y. Li, “... -related adverse events of immune checkpoint inhibitors in the gastrointestinal system: A study based on the US food and drug administration adverse event reporting …,” Frontiers in …, 2021.
O. Akinboro, N. Drezner, A. Amatya, J. Runyan, "US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non …," Journal of Clinical Oncology, vol. 2023.
S. E. Udeabor, "Monoclonal Antibodies in Modern Medicine: Their Therapeutic Potential and Future Directions," Trends in Pharmaceutical Biotechnology, 2024.
Y. Song, J. Li, and Y. Wu, "Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders," Signal Transduction and Targeted Therapy, 2024.
J. F. Santos-Neto, F. O. Oliveira, K. V. S. Hodel, et al., "Technological advancements in monoclonal antibodies," *The Scientific World Journal*, vol. 2021, 2021.
X. K. Chi, X. L. Xu, B. Y. Chen, J. Su et al., "Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments," Journal of Nanobiotechnology, 2023.
S. Delhalle, S. F. N. Bode, R. Balling, M. Ollert et al., "A roadmap towards personalized immunology.," 2018.
M. Afzal, A. K. Sah, S. Agarwal, A. Tanzeel, "Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine," Trends in ..., 2024.
Kayser, L. A. Dutra, E. T. dos Reis-Neto, et al., "The role of autoantibody testing in modern personalized medicine," *Clinical Reviews in*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. Springer.
IJ Tan, A. Podwojniak, A. Parikh, and B. A. Cohen, "Precision dermatology: a review of molecular biomarkers and personalized therapies," Issues in Molecular Biology, 2024.
Y. Vojgani and N. Zeynalniya Toosi, "Personalized Medicine Approach in the Treatment and Status of Autoimmune Diseases," Advanced Therapies Journal, 2024.
R. Giacomelli, A. Afeltra, E. Bartoloni, O. Berardicurti, et al., "The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus," *Autoimmunity*, vol. XX, no. XX, pp. XX-XX, 2021.
J. Peng, E. C. Jury, P. Dönnes, and C. Ciurtin, "Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges," Frontiers in pharmacology, 2021.
Ceribelli, F. Motta, M. Vecellio, N. Isailovic, "Clinical trials supporting the role of the IL-17/IL-23 axis in axial spondyloarthritis," Frontiers in…, vol. 2021.
Eshwar, A. Kamath, R. Shastry, A. K. Shenoy et al., "A review of the safety of interleukin-17A inhibitor secukinumab," Pharmaceuticals, 2022.
M. Song, J. Liang, L. Wang, W. Li, S. Jiang, S. Xu, "IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment," *International Journal*, vol. 2023, Elsevier.
F. Atzeni, A. Carriero, L. Boccassini, et al., "Anti-IL-17 agents in the treatment of axial spondyloarthritis," ImmunoTargets and Therapy, vol. 2021, Taylor & Francis.
F. Caso, A. Saviano, N. Marigliano, "IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies," *Review of Clinical*, 2025.
Jiang, Y. Du, X. Liu, J. Wang, C. Ge, J. Xu, "Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with …," *British Journal of …*, 2024.
F. W. Miller, "The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention," Current opinion in immunology, 2023.
P. Li, Y. X. Han, Y. S. He, Y. Wen, Y. C. Liu, Z. Y. Fu, et al., "A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040," Autoimmunity, vol. 2023, Elsevier.
Greiner, K. Patel, C. J. Crossman-Barnes, et al., "High-expenditure disease in the EU-28: does drug spend correspond to clinical and economic burden in oncology, autoimmune disease and diabetes?," PharmacoEconomics, vol. 39, no. 1, pp. 1-15, 2021.
J. D. Paul, T. Lutsiv, and H. J. Thompson, "A Perennial Green Revolution to address 21st‐century food insecurity and malnutrition," Food and Energy Security, 2024
Copyright (c) 2025 Thikra Majid Muhammed
This work is licensed under a Creative Commons Attribution 4.0 International License.
